Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604269 | 1.00 | DRD2 (0.33) | DRD2ADRA1DADRA1AADRA1BSLC2A1 | |
| SCHEMBL604270 | 1.00 | DRD2 (0.33) | DRD2ADRA1DADRA1AADRA1BSLC2A1 | |
| SCHEMBL604342 | 0.85 | CHRM4 (0.38) | DRD2ADRA1DADRA1AADRA1BUSP30 | |
| SCHEMBL604341 | 0.85 | CHRM4 (0.38) | DRD2ADRA1DADRA1AADRA1BUSP30 | |
| SCHEMBL608210 | 0.82 | CHRM4 (0.36) | DRD2ADRA1DADRA1AADRA1BUSP30 | |
| SCHEMBL608209 | 0.82 | CHRM4 (0.36) | DRD2ADRA1DADRA1AADRA1BUSP30 | |
| SCHEMBL550734 | 0.76 | SLC18A3 (0.53) | DRD2SLC18A3PDCD1CD274OPRM1 | |
| SCHEMBL10203597 | 0.72 | CHRM1 (0.37) | CHRM1CHRM4CHRM2 | |
| SCHEMBL608254 | 0.69 | IRAK4 (0.35) | — | |
| SCHEMBL604633 | 0.69 | IRAK4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | DRD2 225/4885ADRA1D 113/4885ADRA1A 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.